| Lower glycemic targets did not produce large reductions in fetal overgrowth, but they were associated with a higher rate of inductions. As there were no observed differences in maternal or neonatal outcomes otherwise, aiming for lower glycemic targets in GDM is likely not cost-effective (Journal of Diabetes Research)
Data from RCTs do not show an increased risk of FG among patients, unlike pharmacovigilance reports, but the number of recorded cases is small (Diabetes, Obesity and Metabolism)
The addition of empagliflozin to anti‐hyperglycemic regimens of patients with type 2 diabetes and CV disease consistently reduced their risks of adverse CV outcomes and mortality irrespective of baseline use of metformin, sulfonylurea, or insulin. For CKD progression, there may be a larger benefit from empagliflozin in those patients who are not using metformin (Diabetes, Obesity and Metabolism)
DPP‐4 inhibition has persistent daytime effects on glucose, islet and incretin hormones with no difference between three different DPP‐4 inhibitors (Diabetes, Obesity and Metabolism)
A cohort study using primary care data from the United Kingdom (Primary Care Diabetes)
| 